Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Sep 24, 2026; 17(9): 123454
Published online Sep 24, 2026. doi: 10.5306/wjco.123454
Published online Sep 24, 2026. doi: 10.5306/wjco.123454
Efficacy of transcatheter arterial embolization plus targeted chemotherapy for advanced hepatocellular carcinoma: A case report and literature review
Si-Lei Yu, Department of Graduate Education, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Jin-E Liu, Yong-Qi Shen, Department of Oncology, Liutie Central Hospital, Liuzhou 545007, Guangxi Zhuang Autonomous Region, China
Chun-Ying Li, Hao Ling, Department of Pathology, Liutie Central Hospital, Liuzhou 545007, Guangxi Zhuang Autonomous Region, China
Hai-Yun Tao, Department of Tumor Hematology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou 545002, Guangxi Zhuang Autonomous Region, China
Co-first authors: Si-Lei Yu and Jin-E Liu.
Co-corresponding authors: Hai-Yun Tao and Yong-Qi Shen.
Author contributions: Yu SL was responsible for clinical diagnosis and treatment of the patient, drafting the original manuscript and journal submission. Liu JE formulated the treatment protocols and participated in joint patient management. Li CY collected clinical data. Ling H was responsible for the patient’s follow-up data. Tao HY and Shen YQ served as co-corresponding authors, and both authors made equally vital contributions to the research and manuscript, which is the core reason for their appointment as joint corresponding authors. Shen YQ designed the overall research framework and therapeutic regimens, and conducted study quality control throughout the entire clinical observation and manuscript writing process. He was responsible for project application, implementation and quality supervision of this clinical study supported by Liuzhou Municipal Bureau of Science and Technology (Contract No.: 2019BJ10613), verified the authenticity and integrity of all clinical, imaging and pathological data, repeatedly revised the core argumentation of the Discussion section, and coordinated all authors in the provision of supplementary research evidence. Tao HY performed manuscript review and critical revision, took final responsibility for the reliability of this study, and focused on collecting, sorting and quoting the latest global HCC guidelines, relevant clinical trial literature and mechanism studies. She also provided in-depth interpretations of the patient’s special clinical features and completed targeted revisions according to each peer reviewer’s detailed comments. The long-term collaborative research between Tao HY and Shen YQ integrates their respective professional skills in tumor hematology and clinical oncology. Their complementary academic perspectives jointly guaranteed the scientific rationality and clinical reference value of this case report, and the complete research and manuscript polishing was not completed by either author alone; all authors have read and approved the final manuscript.
AI contribution statement: AI tools were used solely for linguistic refinement and formatting assistance. No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. All AI-generated outputs were critically reviewed and revised by the authors.
Supported by Liuzhou Municipal Bureau of Science and Technology: Clinical Study of TAE Sequential Anlotinib Combined with Oxaliplatin plus Raltitrexed in the Treatment of Advanced Hepatocellular Carcinoma, No. 2019BJ10613.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Yong-Qi Shen, MD, Chief Physician, Department of Oncology, Liutie Central Hospital, No. 14 Limin Community, Fei’e Road, Liunan District, Liuzhou 545007, Guangxi Zhuang Autonomous Region, China. gxnnsyq@163.com
Received: May 19, 2026
Revised: July 21, 2026
Accepted: August 20, 2026
Published online: September 24, 2026
Processing time: 127 Days and 17.5 Hours
Revised: July 21, 2026
Accepted: August 20, 2026
Published online: September 24, 2026
Processing time: 127 Days and 17.5 Hours
Core Tip
Core Tip: This case reports a 52-year-old patient diagnosed with hepatocellular carcinoma (CNLC stage IIIB) complicated by active clonorchiasis—an immunotherapy contraindication. The patient received transcatheter arterial embolization followed by sequential oxaliplatin, raltitrexed, and anlotinib, achieving partial response and progression-free survival exceeding 50 months. This regimen may offer a viable alternative for immunotherapy-ineligible advanced hepatocellular carcinoma patients, although long-term efficacy requires further validation.